Evaluation of Chemotherapy With Streptozotocin Combined With 5-Fluorouracil and Adriamycin in Patients With Zollinger-Ellison Syndrome and Metastatic Non-Beta-Islet Cell Neoplasm
Heretofore morbidity and risk of death in Zollinger-Ellison syndrome were caused by severe
ulcer disease. The advent of specific drugs to cure ulcer disease now extends life until
metastases from the non-beta-islet cell tumor cause death. The present study proposes to
continue to test the effect of combined chemotherapy with streptozotocin, 5-fluorouracil and
doxorubicin in biopsy-proven cases of metastatic non-beta-islet cell tumor in patients with
Zollinger-Ellison syndrome. We published our initial experience with this protocol in 1988.
An objective response was observed in 40% of patients.
Interventional
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
United States: Federal Government
780133
NCT00001165
September 1978
August 2003
Name | Location |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Bethesda, Maryland 20892 |